Targeting metabolic syndrome: candidate natural agents
1Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Journal of Diabetes
|October 7, 2010
Summary
Metabolic syndrome, characterized by hyperglycemia, hypertriglyceridemia, hypertension, and obesity, is prevalent in China. This review explores nine natural agents derived from traditional medicine for potential multi-target treatments of metabolic syndrome.
Area of Science:
- Metabolic Medicine
- Traditional Chinese Medicine
- Pharmacology
Background:
- China faces a high prevalence of metabolic syndrome, a condition marked by hyperglycemia, hypertriglyceridemia, hypertension, and central obesity.
- Current treatments often address only one component of metabolic syndrome, highlighting a need for multi-target therapies.
- Natural agents show promise for managing the complex metabolic abnormalities associated with this syndrome.
Purpose of the Study:
- To review the evidence supporting the use of nine natural agents for treating metabolic syndrome.
- To evaluate traditional medicine-based preparations as potential multi-target therapies for metabolic syndrome.
- To explore novel therapeutic avenues for the "Deadly Quartet" of metabolic syndrome.
Main Methods:
- Literature review of scientific studies on natural agents and metabolic syndrome.
- Analysis of traditional medicine and herbal preparations with potential therapeutic benefits.
- Synthesis of evidence on agents targeting hyperglycemia, hypertriglyceridemia, hypertension, and obesity.
Main Results:
- Nine natural agents, rooted in traditional medicine, demonstrate potential in addressing multiple facets of metabolic syndrome.
- Evidence suggests these agents can concurrently manage hyperglycemia, hypertriglyceridemia, hypertension, and central obesity.
- The review consolidates findings on the efficacy and mechanisms of these natural compounds.
Conclusions:
- Natural agents offer a promising, multi-targeted approach to managing metabolic syndrome.
- Traditional medicine provides a valuable source for developing novel treatments for metabolic syndrome.
- Further research into these agents could lead to improved therapeutic strategies for metabolic syndrome patients.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...